Please provide your email address to receive an email when new articles are posted on . Focal cortex stimulation with an implantable device reduced seizure activity in more than 50% of participants at ...

Please provide your email address to receive an email when new articles are posted on . XEN1101 is a novel small-molecule selective Kv7.2/Kv7.3 potassium channel opener. A 25 mg dose of XEN1101 ...

Focal-onset seizures (FOSs) are the most common type of seizure experienced by epileptic individuals. A recent randomized control trial published in JAMA Neurology evaluated the effect of a novel ...

LONDON, June 05, 2025--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced completion of the CORE-VNS study, evaluating comprehensive outcomes of ...

Post-hoc analysis from open-label Phase 3 study shows treatment with cenobamate led to a reduction of concomitant anti-seizure medications (ASMs) while maintaining ≥50% and 100% seizure reduction ...

Median Reduction of Seizure Frequency of 35.7% Over Placebo was Achieved in the 60 mg Treatment Arm Neurological Effects and Other Adverse Effects (AEs) Similar to Placebo NEW YORK, Jan. 30, 2023 ...

The US Food and Drug Administration (FDA) has approved cenobamate (Xcopri, SK Life Science) for the treatment of partial-onset seizures in adult patients with epilepsy. Today's approval was based on ...

The product is an anti-seizure medication (ASM) approved in Europe as adjunctive treatment of focal-onset seizures with or without secondary generalization in adult patients living with epilepsy who ...

Researchers have discovered that light from an ultraviolet diode (UV LED) reduced "seizure-like" activity in a rat epilepsy model. Results of this study have considerable potential in treating focal ...

BOSTON — Preliminary results from a meta-analysis have shown that antiepileptic drugs (AEDs) approved for adults with primary generalized tonic-clonic (PGTC) seizures are also effective in children ...

Long-term, real-world evidence demonstrates early and lasting outcomes of adjunctive VNS Therapy on severe focal seizures “It is critically important to conduct long-term, real-world studies like CORE ...